These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

337 related articles for article (PubMed ID: 22448595)

  • 41. A drug discovery case history of 'delta-9-tetrahydrocannabinol, cannabidiol'.
    Tanasescu R; Rog D; Constantinescu CS
    Expert Opin Drug Discov; 2011 Apr; 6(4):437-52. PubMed ID: 22646020
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cannabinoids for the Treatment of Agitation and Aggression in Alzheimer's Disease.
    Liu CS; Chau SA; Ruthirakuhan M; Lanctôt KL; Herrmann N
    CNS Drugs; 2015 Aug; 29(8):615-23. PubMed ID: 26271310
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cannabinoids in late-onset Alzheimer's disease.
    Ahmed A; van der Marck MA; van den Elsen G; Olde Rikkert M
    Clin Pharmacol Ther; 2015 Jun; 97(6):597-606. PubMed ID: 25788394
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Understanding the Modulatory Effects of Cannabidiol on Alzheimer's Disease.
    Xiong Y; Lim CS
    Brain Sci; 2021 Sep; 11(9):. PubMed ID: 34573232
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modulation of Oxidative Stress and Neuroinflammation by Cannabidiol (CBD): Promising Targets for the Treatment of Alzheimer's Disease.
    Hickey JP; Collins AE; Nelson ML; Chen H; Kalisch BE
    Curr Issues Mol Biol; 2024 May; 46(5):4379-4402. PubMed ID: 38785534
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications.
    Horváth B; Mukhopadhyay P; Haskó G; Pacher P
    Am J Pathol; 2012 Feb; 180(2):432-42. PubMed ID: 22155112
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Under the umbrella of depression and Alzheimer's disease physiopathology: Can cannabinoids be a dual-pleiotropic therapy?
    Fonseca C; Ettcheto M; Bicker J; Fernandes MJ; Falcão A; Camins A; Fortuna A
    Ageing Res Rev; 2023 Sep; 90():101998. PubMed ID: 37414155
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Can We Treat Neuroinflammation in Alzheimer's Disease?
    Sánchez-Sarasúa S; Fernández-Pérez I; Espinosa-Fernández V; Sánchez-Pérez AM; Ledesma JC
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228179
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Potential and Limits of Cannabinoids in Alzheimer's Disease Therapy.
    Abate G; Uberti D; Tambaro S
    Biology (Basel); 2021 Jun; 10(6):. PubMed ID: 34204237
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Advances in quantitative structure-activity relationship models of anti-Alzheimer's agents.
    Ambure P; Roy K
    Expert Opin Drug Discov; 2014 Jun; 9(6):697-723. PubMed ID: 24754675
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Endocannabinoid system, pharmacogenomics and response to therapy.
    Onaivi ES
    Pharmacogenomics; 2010 Jul; 11(7):907-10. PubMed ID: 20602608
    [No Abstract]   [Full Text] [Related]  

  • 52. Therapeutic links between Alzheimer's disease and brain cancer: drug discovery consequences.
    Kraus JL
    ChemMedChem; 2013 May; 8(5):689-92. PubMed ID: 23444291
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Research and development of anti-Alzheimer's drugs: an analysis based on technology flows measured by patent citations.
    Xu J; Kong X; Qiu L; Geng X; Hu Y; Wang Y
    Expert Opin Ther Pat; 2014 Jul; 24(7):791-800. PubMed ID: 24798577
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Endocannabinoids in Alzheimer's disease and their impact on normative cognitive performance: a case-control and cohort study.
    Koppel J; Bradshaw H; Goldberg TE; Khalili H; Marambaud P; Walker MJ; Pazos M; Gordon ML; Christen E; Davies P
    Lipids Health Dis; 2009 Jan; 8():2. PubMed ID: 19144193
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Can the benefits of cannabinoid receptor stimulation on neuroinflammation, neurogenesis and memory during normal aging be useful in AD prevention?
    Marchalant Y; Baranger K; Wenk GL; Khrestchatisky M; Rivera S
    J Neuroinflammation; 2012 Jan; 9():10. PubMed ID: 22248015
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Chronic pain in Alzheimer's disease: Endocannabinoid system.
    Blanton H; Reddy PH; Benamar K
    Exp Neurol; 2023 Feb; 360():114287. PubMed ID: 36455638
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cannabinoids and Dementia: A Review of Clinical and Preclinical Data.
    Walther S; Halpern M
    Pharmaceuticals (Basel); 2010 Aug; 3(8):2689-2708. PubMed ID: 27713372
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Neuropeptides in Alzheimer's Disease: An Update.
    Petrella C; Di Certo MG; Barbato C; Gabanella F; Ralli M; Greco A; Possenti R; Severini C
    Curr Alzheimer Res; 2019; 16(6):544-558. PubMed ID: 31456515
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cannabinoid extract in microdoses ameliorates mnemonic and nonmnemonic Alzheimer's disease symptoms: a case report.
    Ruver-Martins AC; Bicca MA; de Araujo FS; de Noronha Sales Maia BHL; Pamplona FA; da Silva EG; Nascimento FP
    J Med Case Rep; 2022 Jul; 16(1):277. PubMed ID: 35820856
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Emerging Promise of Cannabinoids for the Management of Pain and Associated Neuropathological Alterations in Alzheimer's Disease.
    Uddin MS; Mamun AA; Sumsuzzman DM; Ashraf GM; Perveen A; Bungau SG; Mousa SA; El-Seedi HR; Bin-Jumah MN; Abdel-Daim MM
    Front Pharmacol; 2020; 11():1097. PubMed ID: 32792944
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.